{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:07:48Z","timestamp":1789686468046,"version":"4.0.1"},"reference-count":111,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Conventional psychological and pharmacological substance abuse treatments are limited to moderate effect sizes and fail to magnify outcomes when combined. Analog psychedelic agents N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) show therapeutic potential for treatment-resistant psychiatric disorders including substance addictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis synthesized DMT intervention studies (1960\u20132024) across PubMed, PsycINFO, Web of Science, and EBSCO databases, calculating pooled effects for substance use reduction. Subgroup sensitivity analyses examined the impacts of psychotherapy, population type, and treatment design on outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      DMT yielded a large overall effect size for substance abuse reduction (\n                      <jats:italic toggle=\"yes\">g<\/jats:italic>\n                      \u2009=\u20090.94, 95% CI: 0.56\u20131.31,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), with superior efficacy for drug use (\n                      <jats:italic toggle=\"yes\">g\u2009=<\/jats:italic>\n                      \u20091.35, 95% CI: 0.63\u20132.07,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) compared to alcohol use (\n                      <jats:italic toggle=\"yes\">g<\/jats:italic>\n                      \u2009=\u20090.65, 95% CI: 0.31\u20130.99,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Studies incorporating psychotherapy showed significantly greater effects (\n                      <jats:italic toggle=\"yes\">g<\/jats:italic>\n                      \u2009=\u20091.38, 95% CI: 1.06\u20131.71,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) than those without (\n                      <jats:italic toggle=\"yes\">g<\/jats:italic>\n                      \u2009=\u20090.60, 95% CI: 0.09\u20131.12,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), with significant subgroup difference (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0121). High risk of bias and high heterogeneity were observed (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200996.9%), with effects varying by substance type and treatment context. No publication bias was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>When combined, available studies demonstrate DMT\u2019s potentially substantial post-treatment efficacy for substance misuse, particularly with psychotherapy. Effect magnitudes vary by abused substances. Included studies had substantial methodological limitations and high risk of bias. Reported effects should therefore be interpreted as preliminary rather than indicative of established efficacy. Furthermore, the use of exploratory subgroup analyses in this review can only conclude that DMT efficacy for treating alcohol and substance abuse disorders is highly heterogeneous, depending on study and treatment design. If sustained positive results are clearly demonstrated in future research, it might position DMT-assisted psychotherapy as an effective, economical alternative to conventional treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261430518","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:15:01Z","timestamp":1776014101000},"page":"1224-1246","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5432-0689","authenticated-orcid":false,"given":"Lisa M.","family":"Wallace","sequence":"first","affiliation":[{"name":"Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, UK"},{"name":"Department of Educational Psychology, College of Education, University of Texas at Austin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3359-6146","authenticated-orcid":false,"given":"Andrea","family":"Bujor","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-5413","authenticated-orcid":false,"given":"Gustavo","family":"Sudre","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-8315","authenticated-orcid":false,"given":"Mark","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6398-617X","authenticated-orcid":false,"given":"Diana-Elena","family":"Bahnareanu","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3875-4487","authenticated-orcid":false,"given":"Khushi","family":"Mittal","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_3_3_3_1","volume-title":"Treatment of Patients with Substance Use Disorders","author":"American Psychiatric Association (APA)","year":"2006","unstructured":"American Psychiatric Association (APA) (2006) Treatment of Patients with Substance Use Disorders. American Psychiatric Association Publishing."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615371969"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Andrade C. (2021). The ceiling effect the floor effect and the importance of active and placebo control arms in randomized controlled trials of an investigational drug. Indian Journal of Psychological Medicine 43(4): 360\u2013361. https:\/\/doi.org\/10.1177\/02537176211021280","DOI":"10.1177\/02537176211021280"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Apud I Scuro J Carrera I et al. (2022) Ayahuasca ritual personality and sociality. Observational research conducted in a substance use disorder rehabilitation center in Uruguay. Journal of Psychoactive Drugs 55(2): 1\u201310. https:\/\/doi.org\/10.1080\/02791072.2022.2053004","DOI":"10.1080\/02791072.2022.2053004"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Armstrong SB Xin Y Sepeda ND et al. (2023) Prospective associations of psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. Military Psychology 36(2): 1\u20138. https:\/\/doi.org\/10.1080\/08995605.2022.2156200","DOI":"10.1080\/08995605.2022.2156200"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Balant M Gras A Ruz M et al. (2021) Traditional uses of Cannabis: An analysis of the CANNUSE database. Journal of Ethnopharmacology 279: 114362. https:\/\/doi.org\/10.1016\/j.jep.2021.114362","DOI":"10.1016\/j.jep.2021.114362"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Becker JB McClellan ML Reed BG (2016) Sex differences gender and addiction. Journal of Neuroscience Research 95(1\u20132): 136\u2013147. https:\/\/doi.org\/10.1002\/jnr.23963","DOI":"10.1002\/jnr.23963"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Berlowitz I Walt H Ghasarian C et al. (2019) Short-term treatment effects of a substance use disorder therapy involving traditional Amazonian medicine. Journal of Psychoactive Drugs 51(4): 323\u2013334. https:\/\/doi.org\/10.1080\/02791072.2019.1607956","DOI":"10.1080\/02791072.2019.1607956"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Bogenschutz MP Forcehimes AA Pommy JA et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29(3): 289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144","DOI":"10.1177\/0269881114565144"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Borkel LF Rojas J Alberto L et al. (2023) Set and setting predict psychopathology well-being and meaningfulness of psychedelic experiences: A correlational study. Expert Review of Clinical Pharmacology 17(2): 165\u2013176. https:\/\/doi.org\/10.1080\/17512433.2023.2295997","DOI":"10.1080\/17512433.2023.2295997"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Brown VA (2021) An introduction to linear mixed-effects modeling in R. Advances in Methods and Practices in Psychological Science 4(1): 251524592096035. https:\/\/doi.org\/10.1177\/2515245920960351","DOI":"10.1177\/2515245920960351"},{"issue":"3","key":"e_1_3_3_14_1","first-page":"269","article-title":"Societal burden of substance abuse","volume":"6","author":"Caulkins JP","year":"2014","unstructured":"Caulkins JP, Kasunic A, Lee MAC (2014) Societal burden of substance abuse. International Public Health Journal 6(3): 269.","journal-title":"International Public Health Journal"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Cavarra M Falzone A Ramaekers JG et al. (2022) Psychedelic-assisted psychotherapy\u2014A systematic review of associated psychological interventions. Frontiers in Psychology 13: 887255. https:\/\/doi.org\/10.3389\/fpsyg.2022.887255","DOI":"10.3389\/fpsyg.2022.887255"},{"key":"e_1_3_3_16_1","unstructured":"Cochrane Methods (2017) Risk of Bias 2 (RoB 2) tool. Available at: https:\/\/methods.cochrane.org\/risk-bias-2"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Conway KP Levy J Vanyukov M et al. (2010) Measuring addiction propensity and severity: The need for a new instrument. Drug and Alcohol Dependence 111(1\u20132): 4\u201312. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.03.011","DOI":"10.1016\/j.drugalcdep.2010.03.011"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Corbeil RR Searle SR (1976) Restricted Maximum Likelihood (REML) estimation of variance components in the mixed model. Technometrics 18(1): 31. https:\/\/doi.org\/10.2307\/1267913","DOI":"10.2307\/1267913"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Dakwar E Levin F Hart CL et al. (2019) A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. American Journal of Psychiatry 177(2): 125\u2013133. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19070684","DOI":"10.1176\/appi.ajp.2019.19070684"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Davis AK So S Lancelotta R et al. (2019) 5-methoxy-N N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse 45(2): 161\u2013169. https:\/\/doi.org\/10.1080\/00952990.2018.1545024","DOI":"10.1080\/00952990.2018.1545024"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"De Oliveira J Kerr-Correa F Lima M et al. (2014) Validity of alcohol screening instruments in general population gender studies: An analytical review. Current Drug Abuse Reviews 7(1): 59\u201365. https:\/\/doi.org\/10.2174\/1874473707666141015214708","DOI":"10.2174\/1874473707666141015214708"},{"key":"e_1_3_3_22_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks JJ","year":"2024","unstructured":"Deeks JJ, Higgins JP, Altman DG, et al. (2024) Chapter 10: Analysing data and undertaking meta-analyses. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Del Re AC Fl\u00fcckiger C Horvath AO et al. (2021) Examining therapist effects in the alliance\u2013outcome relationship: A multilevel meta-analysis. Journal of Consulting and Clinical Psychology 89(5): 371\u2013378. https:\/\/doi.org\/10.1037\/ccp0000637","DOI":"10.1037\/ccp0000637"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Delgrasso A (2024) Defining 5-MeO-DMT in historical and cultural contexts. World Futures 80(2): 174\u2013197. https:\/\/doi.org\/10.1080\/02604027.2024.2330255","DOI":"10.1080\/02604027.2024.2330255"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Dellazizzo L Potvin S Gigu\u00e8re S et al. (2023) Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders. Psychiatry Research-Neuroimaging 326: 115318. https:\/\/doi.org\/10.1016\/j.psychres.2023.115318","DOI":"10.1016\/j.psychres.2023.115318"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Downs SH Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology & Community Health 52(6): 377\u2013384. https:\/\/doi.org\/10.1136\/jech.52.6.377","DOI":"10.1136\/jech.52.6.377"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Durlak JA (2009) How to select calculate and interpret effect sizes. Journal of Pediatric Psychology 34(9): 917\u2013928. https:\/\/doi.org\/10.1093\/jpepsy\/jsp004","DOI":"10.1093\/jpepsy\/jsp004"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"F\u00e1bregas JM Gonz\u00e1lez D Fondevila S et al. (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence 111(3): 257\u2013261. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.03.024","DOI":"10.1016\/j.drugalcdep.2010.03.024"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Ferreira AE Reis-Pina P (2025) Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review. Journal of Psychosomatic Research 189: 112020. https:\/\/doi.org\/10.1016\/j.jpsychores.2024.112020","DOI":"10.1016\/j.jpsychores.2024.112020"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"Garcia-Romeu A Griffiths RR Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews 7(3): 157\u2013164. https:\/\/doi.org\/10.2174\/1874473708666150107121331","DOI":"10.2174\/1874473708666150107121331"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Garcia-Romeu A Davis AK Erowid F et al. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33(9): 1088\u20131101. https:\/\/doi.org\/10.1177\/0269881119845793","DOI":"10.1177\/0269881119845793"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Garcia-Romeu A Richards WA (2018) Current perspectives on psychedelic therapy: Use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30(4): 291\u2013316. https:\/\/doi.org\/10.1080\/09540261.2018.1486289","DOI":"10.1080\/09540261.2018.1486289"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Sousa M Jim\u00e9nez-Garrido DF Ona G et al. (2021) Acute psychological adverse reactions in first-time ritual ayahuasca users. Journal of Clinical Psychopharmacology 41(2): 163\u2013171. https:\/\/doi.org\/10.1097\/jcp.0000000000001343","DOI":"10.1097\/JCP.0000000000001343"},{"key":"e_1_3_3_34_1","volume-title":"The GRADE Book Version 1.0 (updated September 2024)","author":"Goldkuhle M","year":"2025","unstructured":"Goldkuhle M, Kreuzberger N, Neumann I, et al. (2025) Principles for assessing the certainty of interventions. In: Neumann I, Sch\u00fcnemann H (eds) The GRADE Book Version 1.0 (updated September 2024). The GRADE Working Group."},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Greer GR Tolbert R (1998) A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs 30(4): 371\u2013379. https:\/\/doi.org\/10.1080\/02791072.1998.10399713","DOI":"10.1080\/02791072.1998.10399713"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Gruber KJ Taylor MF (2006) A family perspective for substance abuse: Implications from the literature. Journal of Social Work Practice in the Addictions 6(1\u20132): 1\u201329. https:\/\/doi.org\/10.1300\/j160v06n01_01","DOI":"10.1300\/J160v06n01_01"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Gupta SK (2011) Intention-to-treat concept: A review. Perspectives in Clinical Research 2(3): 109\u2013112. https:\/\/doi.org\/10.4103\/2229-3485.83221","DOI":"10.4103\/2229-3485.83221"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Hall W (2022) Why was early therapeutic research on psychedelic drugs abandoned? Psychological Medicine 52(1): 26\u201331. https:\/\/doi.org\/10.1017\/S0033291721004207","DOI":"10.1017\/S0033291721004207"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Hartogsohn I (2016) Set and setting psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology 30(12): 1259\u20131267. https:\/\/doi.org\/10.1177\/0269881116677852","DOI":"10.1177\/0269881116677852"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Hartogsohn I (2017) Constructing drug effects: A history of set and setting. Drug Science Policy and Law 3. https:\/\/doi.org\/10.1177\/2050324516683325","DOI":"10.1177\/2050324516683325"},{"key":"e_1_3_3_41_1","doi-asserted-by":"crossref","unstructured":"Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414): 557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_42_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2024","unstructured":"Higgins JP, Li T, Deeks JJ (2024a) Chapter 6: Choosing effect measures and computing estimates of effect. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_43_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2024","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, et al. (2024b) Chapter 8: Assessing risk of bias in a randomized trial. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_3_3_45_1","doi-asserted-by":"crossref","unstructured":"Hoffman RS Goldfrank LR (1990) The impact of drug abuse and addiction on society. Emergency Medicine Clinics of North America 8(3): 467\u2013480. https:\/\/doi.org\/10.1016\/s0733-8627(20)30253-4","DOI":"10.1016\/S0733-8627(20)30253-4"},{"key":"e_1_3_3_46_1","doi-asserted-by":"crossref","unstructured":"Hosseini M-S Jahanshahlou F Akbarzadeh MA et al. (2024) Formulating research questions for evidence-based studies. Journal of Medicine Surgery and Public Health 2: 100046. https:\/\/doi.org\/10.1016\/j.glmedi.2023.100046","DOI":"10.1016\/j.glmedi.2023.100046"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","unstructured":"Humeniuk R Ali R Babor TF et al. (2008) Validation of the alcohol smoking and substance involvement screening test (ASSIST). Addiction 103(6): 1039\u20131047. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.02114.x","DOI":"10.1111\/j.1360-0443.2007.02114.x"},{"key":"e_1_3_3_48_1","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Garrido DF G\u00f3mez-Sousa M Ona G et al. (2020) Effects of ayahuasca on mental health and quality of life in na\u00efve users: A longitudinal and cross-sectional study combination. Scientific Reports 10(1): 4075. https:\/\/doi.org\/10.1038\/s41598-020-61169-x","DOI":"10.1038\/s41598-020-61169-x"},{"key":"e_1_3_3_49_1","doi-asserted-by":"crossref","unstructured":"Johansson BA Berglund M Lindgren A (2006) Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 101(4): 491\u2013503. https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01369.x","DOI":"10.1111\/j.1360-0443.2006.01369.x"},{"key":"e_1_3_3_50_1","doi-asserted-by":"crossref","unstructured":"Kangaslampi S (2023) Association between mystical-type experiences under psychedelics and improvements in well-being or mental health \u2013 A comprehensive review of the evidence. Journal of Psychedelic Studies 7(1): 18\u201328. https:\/\/doi.org\/10.1556\/2054.2023.00243","DOI":"10.1556\/2054.2023.00243"},{"key":"e_1_3_3_51_1","doi-asserted-by":"crossref","unstructured":"Kargbo RB (2024) Innovative psychedelic therapies: Harnessing 5-MeO-DMT and DMT for mental health treatment. ACS Medicinal Chemistry Letters 15(11): 1812\u20131814. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00490","DOI":"10.1021\/acsmedchemlett.4c00490"},{"key":"e_1_3_3_52_1","doi-asserted-by":"crossref","unstructured":"Kavensk\u00e1 V Simonov\u00e1 H (2015) Ayahuasca tourism: Participants in shamanic rituals and their personality styles motivation benefits and risks. Journal of Psychoactive Drugs 47(5): 351\u2013359. https:\/\/doi.org\/10.1080\/02791072.2015.1094590","DOI":"10.1080\/02791072.2015.1094590"},{"key":"e_1_3_3_53_1","doi-asserted-by":"crossref","unstructured":"Lander L Howsare J Byrne M (2013) The impact of substance use disorders on families and children: From theory to practice. Social Work in Public Health 28(3\u20134): 194\u2013205. https:\/\/doi.org\/10.1080\/19371918.2013.759005","DOI":"10.1080\/19371918.2013.759005"},{"key":"e_1_3_3_54_1","volume-title":"Drugs, set & suggestibility","author":"Leary T","year":"1961","unstructured":"Leary T (1961, September 6) Drugs, set & suggestibility. Paper presentation. Annual Meeting of the American Psychological Association, New York, NY."},{"key":"e_1_3_3_55_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre C","year":"2016","unstructured":"Lefebvre C, Glanville J, Briscoe S, et al. (2016). Chapter 4: Searching for and selecting studies. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_56_1","doi-asserted-by":"crossref","unstructured":"Leger RF Unterwald EM (2021) Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. Journal of Psychopharmacology 36(1): 026988112110446. https:\/\/doi.org\/10.1177\/02698811211044688","DOI":"10.1177\/02698811211044688"},{"key":"e_1_3_3_57_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Li T","year":"2024","unstructured":"Li T, Higgins JP, Deeks JJ (2024) Chapter 5: Collecting data. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_58_1","doi-asserted-by":"crossref","unstructured":"Loizaga-Velder A Verres R (2014) Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence\u2014qualitative results. Journal of Psychoactive Drugs 46(1): 63\u201372. https:\/\/doi.org\/10.1080\/02791072.2013.873157","DOI":"10.1080\/02791072.2013.873157"},{"key":"e_1_3_3_59_1","doi-asserted-by":"crossref","unstructured":"Lovakov A Agadullina ER (2021) Empirically derived guidelines for effect size interpretation in social psychology. European Journal of Social Psychology 51(3): 485\u2013504. https:\/\/doi.org\/10.1002\/ejsp.2752","DOI":"10.1002\/ejsp.2752"},{"key":"e_1_3_3_60_1","first-page":"257","volume-title":"Yearbook of Cross-Cultural Medicine and Psychotherapy","author":"Mabit D","year":"1996","unstructured":"Mabit D, Rosa Giove D, Vega J (1996) Takiwasi: The use of amazonian shamanism to rehabilitate drug addicts. In Andritzky W (ed.) Yearbook of Cross-Cultural Medicine and Psychotherapy. International Institute of Cross-Cultural Therapy Research (IIKT), pp. 257\u2013285."},{"key":"e_1_3_3_61_1","doi-asserted-by":"crossref","unstructured":"Madsen MK Fisher PM Burmester D et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44(7): 1328\u20131334. https:\/\/doi.org\/10.1038\/s41386-019-0324-9","DOI":"10.1038\/s41386-019-0324-9"},{"key":"e_1_3_3_62_1","doi-asserted-by":"crossref","unstructured":"Magill M Ray L Kiluk B et al. (2019) A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. Journal of Consulting and Clinical Psychology 87(12): 1093\u20131105. https:\/\/doi.org\/10.1037\/ccp0000447","DOI":"10.1037\/ccp0000447"},{"key":"e_1_3_3_63_1","doi-asserted-by":"crossref","unstructured":"M\u00e4kel\u00e4 K (2004) Studies of the reliability and validity of the Addiction Severity Index. Addiction 99(4): 398\u2013410. https:\/\/doi.org\/10.1111\/j.1360-0443.2003.00665.x","DOI":"10.1111\/j.1360-0443.2003.00665.x"},{"key":"e_1_3_3_64_1","doi-asserted-by":"crossref","unstructured":"McGuinness LA Higgins JPT (2020) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods 12(1): 55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_3_3_65_1","doi-asserted-by":"crossref","unstructured":"McHugh RK Hearon BA Otto MW (2010) Cognitive behavioral therapy for substance use disorders. Psychiatric Clinics of North America 33(3): 511\u2013525. https:\/\/doi.org\/10.1016\/j.psc.2010.04.012","DOI":"10.1016\/j.psc.2010.04.012"},{"key":"e_1_3_3_66_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"McKenzie JE","year":"2024","unstructured":"McKenzie JE, Brennan SE, Ryan RE, et al. (2024a) Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_67_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"McKenzie JE","year":"2024","unstructured":"McKenzie JE, Brennan SE, Ryan RE, et al. (2024b) Chapter 9: Summarizing study characteristics and preparing for synthesis. In Higgins J, Thomas J (eds) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration."},{"key":"e_1_3_3_68_1","doi-asserted-by":"crossref","unstructured":"McLellan AT Luborsky L Cacciola J et al. (1985) New data from the Addiction Severity Index reliability and validity in three centers. The Journal of Nervous and Mental Disease 173(7): 412\u2013423. https:\/\/doi.org\/10.1097\/00005053-198507000-00005","DOI":"10.1097\/00005053-198507000-00005"},{"key":"e_1_3_3_69_1","doi-asserted-by":"crossref","unstructured":"McPheeters M O\u2019Connor EA Riley S et al. (2023) Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. JAMA 330(17): 1653\u20131665. https:\/\/doi.org\/10.1001\/jama.2023.19761","DOI":"10.1001\/jama.2023.19761"},{"key":"e_1_3_3_70_1","doi-asserted-by":"crossref","unstructured":"Miller MJ Albarracin-Jordan J Moore C et al. (2019) Chemical evidence for the use of multiple psychotropic plants in a 1 000-year-old ritual bundle from South America. Proceedings of the National Academy of Sciences 116(23): 11207\u201311212. https:\/\/doi.org\/10.1073\/pnas.1902174116","DOI":"10.1073\/pnas.1902174116"},{"key":"e_1_3_3_71_1","unstructured":"National Institute of Drug Abuse (2020) Treatment and recovery. National Institute on Drug Abuse. Available at: https:\/\/nida.nih.gov\/publications\/drugs-brains-behavior-science-addiction\/treatment-recovery"},{"key":"e_1_3_3_72_1","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence (NICE) (2009) Drug misuse: Psychosocial interventions (CG51). Addiction 104(4): 676\u2013677. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02554_1.x","DOI":"10.1111\/j.1360-0443.2009.02554_1.x"},{"key":"e_1_3_3_73_1","doi-asserted-by":"crossref","unstructured":"Nikolic M Mediano P Froese T et al. (2024) Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner. MedRxiv. https:\/\/doi.org\/10.1101\/2024.09.09.24313316","DOI":"10.1101\/2024.09.09.24313316"},{"key":"e_1_3_3_74_1","doi-asserted-by":"crossref","unstructured":"Orford J Velleman R Natera G et al. (2013) Addiction in the family is a major but neglected contributor to the global burden of adult ill-health. Social Science & Medicine 78: 70\u201377. https:\/\/doi.org\/10.1016\/j.socscimed.2012.11.036","DOI":"10.1016\/j.socscimed.2012.11.036"},{"key":"e_1_3_3_75_1","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372: n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_76_1","doi-asserted-by":"crossref","unstructured":"Pahnke WN Kurland AA Unger S et al. (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA 212(11): 1856\u20131856. https:\/\/doi.org\/10.1001\/jama.1970.03170240060010","DOI":"10.1001\/jama.1970.03170240060010"},{"key":"e_1_3_3_77_1","doi-asserted-by":"crossref","unstructured":"Peill JM Trinci KE Kettner H et al. (2022) Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology 36(1): 31\u201345. https:\/\/doi.org\/10.1177\/02698811211066709","DOI":"10.1177\/02698811211066709"},{"key":"e_1_3_3_78_1","doi-asserted-by":"crossref","unstructured":"Perkins D Pagni BA Sarris J et al. (2022) Changes in mental health well-being and personality following ayahuasca consumption: Results of a naturalistic longitudinal study. Frontiers in Pharmacology 13: 884703. https:\/\/doi.org\/10.3389\/fphar.2022.884703","DOI":"10.3389\/fphar.2022.884703"},{"key":"e_1_3_3_79_1","doi-asserted-by":"crossref","unstructured":"Piper T Small F Brown S et al. (2025) Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. Addiction. Advance online publication.https:\/\/doi.org\/10.1111\/add.16762","DOI":"10.1111\/add.16762"},{"key":"e_1_3_3_80_1","doi-asserted-by":"crossref","unstructured":"Politi M Friso F Mabit J (2018) Plant based assisted therapy for the treatment of substance use disorders - part 1. The case of Takiwasi center and other similar experiences. Cultura Y Droga 23(26): 99\u2013126. https:\/\/doi.org\/10.17151\/culdr.2018.23.26.6","DOI":"10.17151\/culdr.2018.23.26.6"},{"key":"e_1_3_3_81_1","doi-asserted-by":"crossref","unstructured":"Preller KH Duerler P Burt JB et al. (2020) Psilocybin induces time-dependent changes in global functional connectivity. Biological Psychiatry 88(2): 197\u2013207. https:\/\/doi.org\/10.1016\/j.biopsych.2019.12.027","DOI":"10.1016\/j.biopsych.2019.12.027"},{"key":"e_1_3_3_82_1","doi-asserted-by":"crossref","unstructured":"Preller KH Herdener M Pokorny T et al. (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Current Biology 27(3): 451\u2013457. https:\/\/doi.org\/10.1016\/j.cub.2016.12.030","DOI":"10.1016\/j.cub.2016.12.030"},{"key":"e_1_3_3_83_1","doi-asserted-by":"crossref","unstructured":"Pustejovsky JE Chen M (2023) Equivalences between ad hoc strategies and meta-analytic models for dependent effect sizes. MetaArXiv preprints. https:\/\/doi.org\/10.31222\/osf.io\/pw54r","DOI":"10.31222\/osf.io\/pw54r_v1"},{"key":"e_1_3_3_84_1","doi-asserted-by":"crossref","unstructured":"Pustejovsky JE Tipton E (2021) Meta-analysis with robust variance estimation: Expanding the range of working models. Prevention Science 23(3): 425\u2013438. https:\/\/doi.org\/10.1007\/s11121-021-01246-3","DOI":"10.1007\/s11121-021-01246-3"},{"key":"e_1_3_3_85_1","doi-asserted-by":"crossref","unstructured":"Ray LA Meredith LR Kiluk BD et al. (2020) Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders. JAMA Network Open 3(6): e208279. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.8279","DOI":"10.1001\/jamanetworkopen.2020.8279"},{"key":"e_1_3_3_86_1","doi-asserted-by":"crossref","unstructured":"Reckweg JT Uthaug MV Szabo A et al. (2022) The clinical pharmacology and potential therapeutic applications of 5-methoxy-N N-dimethyltryptamine (5-MeO-DMT). Journal of Neurochemistry 162(1): 128\u2013146. https:\/\/doi.org\/10.1111\/jnc.15587","DOI":"10.1111\/jnc.15587"},{"key":"e_1_3_3_87_1","first-page":"51","volume-title":"Burden of Disease: The Epidemiological Aspects of Addiction","author":"Rehm J","year":"2020","unstructured":"Rehm J, Probst C, Llamosas Falc\u00f3n L, et al. (2020) Burden of Disease: The Epidemiological Aspects of Addiction. Springer EBooks, pp. 51\u201364."},{"key":"e_1_3_3_88_1","doi-asserted-by":"crossref","unstructured":"Reinert DF Allen JP (2002) The Alcohol Use Disorders Identification Test (AUDIT): A review of recent research. Alcoholism: Clinical and Experimental Research 26(2): 272\u2013279. https:\/\/doi.org\/10.1111\/j.1530-0277.2002.tb02534.x","DOI":"10.1111\/j.1530-0277.2002.tb02534.x"},{"key":"e_1_3_3_89_1","doi-asserted-by":"crossref","unstructured":"Rhemtulla M Fried EI Aggen SH et al. (2016) Network analysis of substance abuse and dependence symptoms. Drug and Alcohol Dependence 161: 230\u2013237. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.02.005","DOI":"10.1016\/j.drugalcdep.2016.02.005"},{"key":"e_1_3_3_90_1","doi-asserted-by":"crossref","unstructured":"Richard J Garcia-Romeu A (2025) Psychedelics in the treatment of substance use disorders and addictive behaviors: A scoping review. Current Addiction Reports 12(1): 15. https:\/\/doi.org\/10.1007\/s40429-025-00629-8","DOI":"10.1007\/s40429-025-00629-8"},{"key":"e_1_3_3_91_1","doi-asserted-by":"crossref","unstructured":"Rodrigues LS Reis JAS Rossi GN et al. (2024) Effects of a single dose of ayahuasca in college students with harmful alcohol use. Journal of Clinical Psychopharmacology 44(4): 402\u2013406. https:\/\/doi.org\/10.1097\/jcp.0000000000001872","DOI":"10.1097\/JCP.0000000000001872"},{"key":"e_1_3_3_92_1","doi-asserted-by":"crossref","unstructured":"Roseman L Haijen E Idialu-Ikato K et al. (2019) Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Journal of Psychopharmacology 33(9): 1076\u20131087. https:\/\/doi.org\/10.1177\/0269881119855974","DOI":"10.1177\/0269881119855974"},{"key":"e_1_3_3_93_1","doi-asserted-by":"crossref","unstructured":"Rothberg RL Azhari N Haug NA et al. (2021) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized controlled trial. Journal of Psychopharmacology 35(2): 150\u2013158. https:\/\/doi.org\/10.1177\/0269881120970879","DOI":"10.1177\/0269881120970879"},{"key":"e_1_3_3_94_1","doi-asserted-by":"crossref","unstructured":"Rush B Marcus O Garc\u00eda S et al. (2021) Protocol for outcome evaluation of ayahuasca-assisted addiction treatment: The case of Takiwasi Center. Frontiers in Pharmacology 12: 659644. https:\/\/doi.org\/10.3389\/fphar.2021.659644","DOI":"10.3389\/fphar.2021.659644"},{"key":"e_1_3_3_95_1","doi-asserted-by":"crossref","unstructured":"Rush B Marcus O Garc\u00eda S et al. (2024) Ayahuasca Treatment Outcome Project (ATOP): One year results from Takiwasi Center and implications for psychedelic science. Journal of Studies on Alcohol and Drugs 85(5): 607\u2013618. https:\/\/doi.org\/10.15288\/jsad.23-00005","DOI":"10.15288\/jsad.23-00005"},{"key":"e_1_3_3_96_1","doi-asserted-by":"crossref","unstructured":"Selin KH (2003). Test-retest reliability of the alcohol use disorder identification test in a general population sample. Alcoholism Clinical and Experimental Research 27(9): 1428\u20131435. https:\/\/doi.org\/10.1097\/01.alc.0000085633.23230.4a","DOI":"10.1097\/01.ALC.0000085633.23230.4A"},{"key":"e_1_3_3_97_1","doi-asserted-by":"crossref","unstructured":"Sherwood AM Claveau R Lancelotta R et al. (2020) Synthesis and characterization of 5-MeO-DMT succinate for clinical use. ACS Omega 5(49): 32067\u201332075. https:\/\/doi.org\/10.1021\/acsomega.0c05099","DOI":"10.1021\/acsomega.0c05099"},{"key":"e_1_3_3_98_1","doi-asserted-by":"crossref","unstructured":"Shinozuka K Tabaac BJ Arenas A et al. (2024) Psychedelic therapy: A primer for primary care clinicians\u2014N N-dimethyltryptamine and ayahuasca. American Journal of Therapeutics 31(2): e112\u2013e120. https:\/\/doi.org\/10.1097\/mjt.0000000000001725","DOI":"10.1097\/MJT.0000000000001725"},{"key":"e_1_3_3_99_1","doi-asserted-by":"crossref","unstructured":"Simon CB McCabe CJ Matson TE et al. (2023) High test\u2013retest reliability of the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire completed by primary care patients in routine care. Alcohol Clinical and Experimental Research 48(2): 302\u2013308. https:\/\/doi.org\/10.1111\/acer.15245","DOI":"10.1111\/acer.15245"},{"key":"e_1_3_3_100_1","doi-asserted-by":"crossref","unstructured":"Sterne JAC Savovi\u0107 J Page MJ et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366(1): l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_3_101_1","unstructured":"Substance Abuse and Mental Health Services Administration (2018) Results from the 2017 National Survey on Drug Use and Health: Detailed tables. Available at: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHDetailedTabs2017\/NSDUHDetailedTabs2017.pdf (accessed 4 March 2025)."},{"key":"e_1_3_3_102_1","doi-asserted-by":"crossref","unstructured":"Talin P Sanabria E (2017) Ayahuasca\u2019s entwined efficacy: An ethnographic study of ritual healing from \u201caddiction.\u201d International Journal of Drug Policy 44: 23\u201330. https:\/\/doi.org\/10.1016\/j.drugpo.2017.02.017","DOI":"10.1016\/j.drugpo.2017.02.017"},{"key":"e_1_3_3_103_1","doi-asserted-by":"crossref","unstructured":"Thomas G Lucas P Capler N et al. (2013) Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Reviews 6(1): 30\u201342. https:\/\/doi.org\/10.2174\/15733998113099990003","DOI":"10.2174\/15733998113099990003"},{"key":"e_1_3_3_104_1","doi-asserted-by":"crossref","unstructured":"Timmermann C Zeifman RJ Erritzoe D et al. (2024) Effects of DMT on mental health outcomes in healthy volunteers. Scientific Reports 14(1): 3097. https:\/\/doi.org\/10.1038\/s41598-024-53363-y","DOI":"10.1038\/s41598-024-53363-y"},{"issue":"6","key":"e_1_3_3_105_1","first-page":"817","article-title":"Addiction and the brain: The role of neurotransmitters in the cause and treatment of drug dependence","volume":"164","author":"Tomkins DM","year":"2001","unstructured":"Tomkins DM, Sellers EM (2001) Addiction and the brain: The role of neurotransmitters in the cause and treatment of drug dependence. CMAJ: Canadian Medical Association Journal 164(6): 817.","journal-title":"CMAJ: Canadian Medical Association Journal"},{"key":"e_1_3_3_106_1","doi-asserted-by":"crossref","unstructured":"Vargas MV Dunlap LE Dong C et al. (2023) Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379(6633): 700\u2013706. https:\/\/doi.org\/10.1126\/science.adf0435","DOI":"10.1126\/science.adf0435"},{"key":"e_1_3_3_107_1","doi-asserted-by":"crossref","unstructured":"Volkow ND Michaelides M Baler R (2019) The neuroscience of drug reward and addiction. Physiological Reviews 99(4): 2115\u20132140. https:\/\/doi.org\/10.1152\/physrev.00014.2018","DOI":"10.1152\/physrev.00014.2018"},{"key":"e_1_3_3_108_1","doi-asserted-by":"crossref","unstructured":"WHO ASSIST Working Group (2002) The Alcohol Smoking and Substance Involvement Screening Test (ASSIST): Development reliability and feasibility. Addiction 97(9): 1183\u20131194. https:\/\/doi.org\/10.1046\/j.1360-0443.2002.00185.x","DOI":"10.1046\/j.1360-0443.2002.00185.x"},{"key":"e_1_3_3_109_1","unstructured":"World Health Organization (WHO) (2018) ICD-11 for mortality and morbidity statistics. Available at: https:\/\/icd.who.int\/dev11\/l-m\/en#\/http:\/\/id.who.int\/icd\/entity\/590211325 (accessed 4 March 2025)."},{"key":"e_1_3_3_110_1","doi-asserted-by":"crossref","unstructured":"Yao Y Guo D Lu T-S et al. (2024) Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research (Print) 335(1): 115886. https:\/\/doi.org\/10.1016\/j.psychres.2024.115886","DOI":"10.1016\/j.psychres.2024.115886"},{"key":"e_1_3_3_111_1","doi-asserted-by":"crossref","unstructured":"Zakiniaeiz Y Potenza MN (2018) Gender-related differences in addiction: A review of human studies. Current Opinion in Behavioral Sciences 23: 171\u2013175. https:\/\/doi.org\/10.1016\/j.cobeha.2018.08.004","DOI":"10.1016\/j.cobeha.2018.08.004"},{"key":"e_1_3_3_112_1","doi-asserted-by":"crossref","unstructured":"Zangiabadian M Golmohammadi S Nejadghaderi SA et al. (2022) The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis. Frontiers in Psychiatry 13: 1003257. https:\/\/doi.org\/10.3389\/fpsyt.2022.1003257","DOI":"10.3389\/fpsyt.2022.1003257"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261430518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261430518","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261430518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:16:19Z","timestamp":1785734179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261430518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/02698811261430518"],"URL":"https:\/\/doi.org\/10.1177\/02698811261430518","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}